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More than 80% of an administered dose of fluorouracil (FU) is elim-
inated by catabolism through dihydropyrimidine dehydrogenase
(DPD), the rate-limiting enzyme of pyrimidines (Diasio and Harris,
1989). Tuchman and colleagues (1985) were the first to describe a
patient with severe FU toxicity associated with a pyrimidine metabo-
lism disorder. On the basis of another case report, Diasio et al (1988)
conducted a familial study, the conclusions of which suggested an
autosomal recessive pattern of inheritance for DPD deficiency. Since
then, similar pharmacogenetic syndromes have been reported by the
same group (Harris et al, 1991; Lu et al, 1993), others (Houyau et al,
1993) and ourselves (Fleming et al, 1993). We recently performed a
review analysis on previously published cases of DPD deficiency
associated with FU toxicity. It appeared that a complete absence of
DPD activity is extremely rare and even partial enzyme activity
might result in more or less severe FU toxicity (Milano and Etienne,
1994). In addition, the fact that among 15 cumulated cases (most
with digestive cancer) 13 (87%) were women was very striking and
suggestive of a sex-linked deficiency in DPD activity. We report on
the clinical and pharmacological results from 19 cancer patients with
more or less intense FU-related toxicity, who were phenotyped in our
centre as carrying a DPD deficiency diagnosed in peripheral blood
mononuclear cells. Different features were analysed including sex
ratio, the toxicity profile, and a possible link between the intensity of
DPD deficiency and the severity of FU toxicity.
MATERIAL AND METHODS
Patients
This study represents a 3-year collection of blood lymphocytes
taken from 53 consecutive patients treated by FU-based
chemotherapy in different French institutions (general hospitals,
cancer centres, private hospitals). These patients had experienced
unpredicted more or less severe FU-related toxicity. Blood lympho-
cytes were collected in the respective hospitals within a period of
1 month after the FU toxicity episode. All lymphocyte samples were
shipped in dry-ice to our laboratory. Among this group of 53
patients (23 men, 30 women, mean age 58, range 36—73), 19 exhib-
ited a moderate or marked DPD deficiency (less than 70% of the
mean population value, i.e. less than 150 fmol min—1 mg—1 protein;
Etienne et al, 1994). A complete description of these 19 case reports
is given in Table 1. We defined a toxicity score which was the sum
of the toxicity grades (WHO classification) for mucositis,
neutropenia, thrombocytopenia and digestive toxicity. The presence
of neurotoxicity was graded 4. The maximal toxicity score was 20.
Determination of DPD activity
Lymphocyte preparation was carried out in the hospital where the
patient received the FU-based treatment. Because of a known
circadian pattern of DPD activity (Harris et al, 1990), blood
samples were drawn between 8 a.m. and 10 a.m. to minimize the
influence of circadian variability. When patients developed severe
haematological toxicity, a normalization of blood cell count (white
blood cells) was awaited before collecting blood samples for DPD
determination. The lymphocytes were prepared as previously
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and allow a more precise definition of the DD toxicity profile.
Keywords: 5-fluorouracil; dihydropyrimidine dehydrogenase; anti-cancer drug-related toxicity
627
British Journal of Cancer (1999) 79(3/4), 627–630
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0098
Received 16 January 1998
Revised 30 April 1998
Accepted 9 May 1998
Correspondence to: G Milanodescribed (Fleming et al, 1993). All the lymphocyte pellets were
brought to our centre, where they were kept at —80°C, and DPD
determination was performed within 2 weeks. DPD activity was
determined as previously described (Fleming et al, 1993). Briefly,
the assay involved incubating lymphocyte extract (cytosol) with
[14C]FU, followed by high-performance liquid chromatography
(HPLC) separation and quantification of [14C]FUH2. Enzyme
activity was expressed as fmol of FUH2 formed per minute and per
milligram of protein. The sensibility limit was 10 pmol min—1 mg—1
protein. The interassay reproducibility (aliquots of a pooled
lymphocyte suspension) gave a coefficient of variation of 12%.
Statistics
Comparisons of frequencies were carried out by chi-squared test.
Group comparisons were carried out by the Mann—Whitney test.
Statistics were drawn up on SPSS software (Chicago, IL, USA).
RESULTS
Table 1 summarizes the clinical, pharmacological and biological
data concerning the 19 study patients with unanticipated FU-
related toxicity and significant DPD deficiency (lymphocytic
DPD activity below 150 pmol min—1 mg—1 protein). Most FU
chemotherapy protocols included FU modulation by folinic acid
(12 out of 19, 63%). In four cases, patients had previously received
a FU-based chemotherapy (more than 1 year before the present
treatment). In two of them, patients 14 and 15, it was possible to
retrieve an indication of FU-related toxicity (mild neurotoxicity
for patient 14 and haematological toxicity for patient 15). There
was a marked majority of women in this group of DPD deficient
patients (15 out of 19, 79%). This population of women was
significantly higher (P = 0.014) than that found in the remaining
34 patients (15 women out of 34, 44%), whose DPD was higher
than 150 pmol min—1 mg—1 protein. Toxicities were often severe,
leading to patient death in two cases (both women). The toxicity
profile was typically related to FU in most cases (mucositis,
neutropenia). The toxicity score was significantly higher in
patients with markedly low DPD (below 100 pmol min—1 mg—1
protein) compared with patients with moderate DPD deficiency
(below 150 and above or equal to 100 pmol min—1 mg—1 protein);
the mean values of the toxicity score were 13.2 ± 5.9 (n = 11) and
6.8 ± 3.7 (n = 8) respectively (P = 0.008). There was a high
proportion of neurotoxic syndromes (7 out of 19, 37%). The two
deceased patients both had neurotoxicity. In contrast, the occur-
rence of cardiac toxicity was relatively rare (1 out of 19, 5%).
DISCUSSION
The present study provides clinical, pharmacological and biolog-
ical data concerning 19 new cases of FU toxicity in relation to
DPD deficiency. The group of patients analysed in the study repre-
sents more than the total number of isolated case reports published
so far in the literature. The notion of DPD deficiency is hard to
delineate precisely because it has been dependent upon the deter-
mination of lymphocytic DPD activity performed by different
laboratories and, thus, included some degree of unavoidable
analytical variability. The present prospective investigation
performed in a single site had the advantage of avoiding this
predictable interinstitution variability in DPD determination. After
the analysis of lymphocyte samples taken from 53 patients who
had developed an unexpected, more or less severe, FU-related
toxicity, 19 (36%) revealed a relative DPD deficiency (below
150 pmol min—1 mg—1 protein, i.e. less than 70% of the mean popu-
lation value; Etienne et al, 1994). Similarly, Lu et al (1993)
reported that in 25 cancer patients who had experienced moderate
to severe FU-related toxicity, nine (36%) were found to have
demonstrated a more or less marked DPD deficiency at lympho-
cyte level. It is clear that causes other than DPD deficiency can
predispose to FU toxicity; these causes may include impaired liver
function (Floyd et al, 1982) and altered nutritional status (Stenram,
1993). It was not within the scope of the present study to investi-
gate thoroughly the diverse origins of the FU-attributed toxic
manifestations after FU-based chemotherapy in the whole group
of patients.
One of the main findings which emerged from the exploration
of the study patients is that the great majority of cases are women
(79%). This observation cannot be explained by a sex-related
tumour profile because most cases were digestive tract cancers.
The proportion of women in the study group was significantly
higher than in the remaining 34 patients from the whole group (15
women out of 34, i.e. 44%), whose DPD activity was not altered.
This observation confirms the conclusions of earlier analyses in
previously published case reports in which it was shown that
women constituted 87% of DPD-deficient patients with FU-
related toxicity (Milano and Etienne, 1994). We recently
performed a prospective study on a large group of 185 unselected
cancer patients (Etienne et al, 1994) and showed that lymphocytic
DPD activity was, on average, 15% lower in women than in men.
Interestingly, this 15% difference in DPD activity was of the order
of magnitude as that observed for FU clearance between men and
women (Milano et al, 1992). In contrast, in a population study by
Lu et al (1993), DPD activity was not influenced by sex. It must be
stressed that the DPD gene is not carried by a sexual chromosome,
but by chromosome 1 (Yokota et al, 1994). Thus, the cause of the
high frequency of women in DPD deficient patients is rather diffi-
cult to explain. The present data show that female patients are
prone to carry a DPD-deficiency syndrome and should be given
priority in systematic investigations of DPD activity before FU-
based chemotherapy. This approach does not preclude careful
consideration of the cost—benefit ratio.
Neurotoxicity is rarely reported among the undesirable side-
effects of FU chemotherapy (Langer et al, 1996). Takimoto and
colleagues (1996) recently reported on a patient with DPD
deficiency who developed severe neurotoxicity after 5FU-based
chemotherapy. The present study clearly indicates that neurotoxi-
city plays a significant part in the toxicity profile exhibited by
DPD-deficient patients after FU treatment. Neurotoxicity was
predominant when DPD deficiency was marked: among the 11
patients with lymphocytic DPD below 100 fmol min—1 mg—1
protein, seven (including two toxic deaths) developed more or less
severe toxicity. The aetiology of FU-related neurotoxicity is still
poorly understood. In agreement with a previous report (Diasio et
al, 1988), it is suggested that neurotoxicity could be attributable to
marked and prolonged exposure to FU in the CSF, secondary to
plasma FU overexposure due to impaired drug clearance related to
the DPD deficiency.
In contrast to neurotoxicity, patients with DPD deficiency did
not present a particularly high incidence of cardiotoxicity because
only one case (5%) was observed in the present study. The mecha-
nisms of FU cardiotoxicity are unknown, but it is probable that this
form of toxicity cannot be accounted for by FU pharmacokinetic
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Table 1 Patients with DPD deficiency
Patient no. Primary FU-based DPD FU-related toxicity
(sex, age) cancer treatment
Lymphocytic D t Mucositis Neutropenia Thrombo- Digestive Neurological Others
activitya (weeks) (grade) (grade) cytopenia toxicity toxicity
(grade) (grade)
1 (F, 66) P FU bolus 143 4 4 4 4 2 No Septicaemia
400 mg m–2 ´ 5 (diarrhoea)
+ adriblastin (cycle 1)
2 (F, 47) C FUFOL 146 4 2 4 No No No Alopecia
(3 h) grade 3
600 mg m–2 day–1 ´ 5
(cycle 1)
3 (F, 60) C FUFOL bolus 101 2 No 2 No No No Cardiotoxicity
375 mg m–2 day–1 ´ 5 alopecia
(cycle 2) grade 3
4 (F, 44) C FU bolus 61,40 12 4 3 3
675 mg m–2 day–1 ´ 5 
+ levamisole (cycle 1)
5 (M, 58) C FUFOL 107 4 No No No 3 No Septicaemia
(cycle 1) (diarrhoea)
6 (F, 56) C FUFOL 65 8 2 No No 2 No
(cycle 1)
7 (F, 61) B FU continuous infusion 34 16 2 No 2 No No
(cycle 1)
8 (F, 48) C FU (48 h) 122 4 3 4 No 1 No
105 mg m–2 day–1
(cycle 1)
9 (F, 45) B FU bolus 900 mg day–1 85 4 4 3–4 3–4 4 Yes
+ novantrone + cytoxin (diarrhoea) (stupor)
(cycle 1)
10 (M, 60) C FUFOL 14 4 4 4 No 4 No
750 mg m–2 day–1
(cycle 4)
11 (M, 66) O FU continuous infusion 88 6 3 4 4 3 Yes
1g  m –2 day–1 ´ 5 + cisplatin (diarrhoea) (cerebellar
(cycle 1) pretreated syndrome)
12 (F, 73) R FUFOL continuous 100 4 3 3 No No No Cutaneous
infusion toxicity
400 mg m–2 day–1 ´ 5
(cycle 1)
13 (F, 63) R FUFOL 122 3 No No No 4 Yes
Oxaliplatin (diarrhoea) (drowsiness
(cycle 1) pretreated confusion)
14 (F, 51) B FU 61 2 4 4 3 4 Yes Toxic death
Navelbine (diarrhoea) (comatose
(cycle 1) pretreated state)
15 (F, 64) C FUFOL 48 3 4 4 4 No Yes Fever
625 mg m–2 day–1 ´ 5 (confusion)
(cycle 1) pretreated
16 (F, 36) C FUFOL 87 2 4 No No 2 No
(cycle 1) (diarrhoea)
17 (F, 52) C FUFOL continuous  135 4 4 4 No No No Alopecia
375 mg m–2 day–1 ´ 5 grade 3
(cycle 1)
18 (M, 68) C FUFOL continuous  53 2 4 4 4 No Yes
425 mg m–2 day–1 (visual
(cycle 1) troubles)
19 (F, 61) P FU cisplatin 10 3 4 4 4 No Yes Toxic death
continuous (comatose
1g  m –2 day–1 ´ 5 state)
(cycle 1)
F, female; M, male; Primary cancer: P, pancreas; C, colon; O, oesophagus; B, breast; R rectum; FU-based treatment: pretreated means pretreated with FU
containing chemotherapy; FUFOL means FU + folinic acid-based chemotherapy; D t means the time interval between the toxic cycle and blood sampling for
DPD determination; apmol min–1 mg–1 protein.abnormalities with drug overexposure due to DPD deficiency. This
view strengthens previous findings by our group in which FU
pharmacokinetic-monitored patients who developed FU-related
cardiotoxicity did not present abnormal FU plasma concentrations
(Thyss et al, 1988).
Another aspect of the present study is the fact that none of the
reported cases had a complete DPD deficiency, even considering
the two female patients who died from severe DPD toxicity.
Patients with moderate DPD deficiency (between 100 and
150 fmol min—1 mg—1 protein) were predisposed to more or less
severe FU-related toxicity. The severity of the toxicity was shown,
however, to match the intensity of the DPD deficiency. This can be
explained by a more or less marked overexposure to FU linked to
the intensity of DPD deficiency because a significant relationship
between lymphocytic DPD activity and FU clearance has been
previously reported (Fleming, 1992).
A molecular basis for DPD deficiency was recently suggested
(Wei et al, 1996). The authors found that a G to A mutation within
the 5¢ splicing site appeared to cause exon skipping, leading to an
inactive DPYD allele. The physical map of the DPD gene was
published recently (Johnson et al, 1997). The classical assay for
DPD activity determinations, as used in the present paper, is
labour intensive and is not to be applied on a large scale. The
recent basic findings concerning DPD should permit the develop-
ment of rapid assays to detect mutations in the DPD gene. But it is
not certain that genotyping will constitute a better solution than the
current phenotyping approach, as different subjects genotyped as
heterozygous for the 5¢ splicing mutation may exhibit highly vari-
able lymphocytic DPD activity among themselves (Wei et al,
1996). Further studies need to be conducted with both genotyping
and phenotyping to assess DPD deficiency and the risk of FU-
related toxicity.
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